Akademiliv

Sahlgrenska akademins nyheter

På Svenska
University of Gothenburg Logotype
  • News
  • Notices
  • Grants
  • About Akademiliv

Reduced risk of bleeding with modern blood thinners

29 August, 2023

NEW STUDY. Modern blood-thinning drugs (known as NOACs) reduce the risk of serious bleeding by up to 45 percent compared to the traditional drug Waran in the treatment of blood clots in the legs and lungs. All according to a comprehensive and long-term study conducted at the University of Gothenburg.

Blood thinners are among the most commonly prescribed drugs. The pharmaceutical substance warfarin has been used for over fifty years and is most commonly known by the brand name Waran. In recent years, other pharmaceutical substances that prevent blood clots have been launched, including a group of four different blood-thinning drugs known as NOACs (non-vitamin K oral anticoagulants). Prior to the introduction of NOACs, studies on short-term treatment regimens showed that such treatment reduced the risk of bleeding compared to Waran. This has resulted in an increasing number of patients who have had a blood clot in the lung or the leg receiving lifelong treatment with this new type of blood thinner.

Extensive Swedish study

For the first time, researchers have now examined the risk of bleeding in both short-term and extended treatment of blood clots in the legs and lungs in a nationwide study in Sweden. The study demonstrates the advantages of NOACs, in particular the substance apixaban, which is marketed under the brand name Eliquis. The study shows that the risk of serious bleeding is 45 percent lower with apixaban compared to warfarin.

Katarina Glise Sandblad
Photo: Karin Lerjestedt Walka

The study’s lead author, Katarina Glise Sandblad, is a doctoral student at Sahlgrenska Academy at the University of Gothenburg as well as a specialist doctor at Sahlgrenska University Hospital:

“We see that apixaban is associated with a lower risk of bleeding in both the short and the long term compared to warfarin. The short-term risk of bleeding is also lower compared to rivaroxaban (Xarelto), another pharmaceutical substance in the NOAC family. The difference between the different drugs is greatest during the initial months of treatment,” says Sandblad.

Small number prescribed Waran

The study is registry-based, encompassing 45,000 patients who took blood-thinning drugs to treat blood clots in the legs or lungs between 2014 and 2020. Of these patients, most were prescribed drugs in the NOAC group: 43 percent were prescribed apixaban and 40 percent were prescribed rivaroxaban. Just under 15 percent were prescribed warfarin. A few were treated with dabigatran (Pradaxa) or edoxaban (Lixiana). The researchers note that the patients prescribed Waran were, on average, older and more likely to have multiple health conditions, which was taken into account in the analyses.

In conclusion, the study shows that apixaban was associated with the lowest risk of bleeding during the first six months of treatment. Rivaroxaban also had a lower risk of bleeding than warfarin, although not as low as apixaban. The difference between apixaban and rivaroxaban was not statistically significant in extended treatment as both of these pharmaceutical substances were associated with a relatively low risk of bleeding (around 1 percent per year).

Some patients need Waran

Although warfarin is prescribed increasingly less, Waran still has a certain role to play as an anticoagulant.

“Today, if a patient is prescribed Waran for the first time by their doctor, in the vast majority of cases it is for good reason, although it can be a good idea for the patient to ask about that reason. This applies to patients with atrial fibrillation as well as those with blood clots in the legs and lungs. Patients who are breastfeeding, or who have a mechanical heart valve or a disorder that disrupts the blood’s ability to coagulate, may need to take Waran instead, but many others could switch to a NOAC,” says Sandblad.

The results of the study are published in the Journal of Internal Medicine.

Title: Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment – a nationwide register-based study.

BY: ELIN LINDSTRÖM

By: Elin Lindström

HAPPY SUMMER!

The newsletter from Akademiliv will return on Wednesday, August 21st.

Contact your institute to add your event to the calendar in the Staff Portal

  • Biomedicine: Kristian Kvint: kalender@biomedicine.gu.se
  • Core Facilities: Amelie Karlsson: amelie.karlsson.2@gu.se
  • Clinical Sciences: Katarina Olinder Eriksson: klinvet@gu.se
  • Medicine: Nina Raun; kommunikation@medicine.gu.se
  • Neuroscience and Physiology: Josefin Bergenholtz; kommunikation@neuro.gu.se
  • Odontology: Johan Thompson; info@odontologi.gu.se
  • Sahlgrenska Academy’s Office and faculty-wide calendar events Åsa Ekvall; info@sahlgrenska.gu.se
  • Health and Care Sciences: Karin Mossberg; vardvetenskap@fhs.gu.se

Information from Sahlgrenska Academy Research Support Office

[UPDATED JUNE 2024]
The Sahlgrenska Academy Research Support Office provides an overview of upcoming and current calls, nominations and events in an information letter. This letter is updated on a monthly basis.
Current and previous newsletters are also available in the Staff Portal.

’20 minutes for researchers’ is back – see full spring program

During 20 minutes over Zoom, the Biomedical Library gives tips on tools and services that can facilitate your research everyday life.

More news

En personlig död (A Personal Death) – a chance to win Björn Fagerberg’s new book

27 May, 2024

NEW BOOK. During his career as a physician specializing in internal medicine, Björn Fagerberg has been involved in many end-of-life situations, …  

She is doing her residency in the US with a medical degree from Gothenburg

21 May, 2024

STUDENT. Doing a “residency” in orthopedics in the United States is an unattainable dream for many newly qualified American doctors. Now Janina Ka …  

Alba Corell reports from a high-level brain tumor meeting

20 May, 2024

COLUMN. The recent gathering of the Scandinavian Society of Neuro-oncology (SNOG) in Gothenburg has concluded. Professor Asgeir Jakola hosted and …  

From South Africa to Sweden: Collaborative Research Efforts Improving Pregnant Women’s Health

17 May, 2024

GLOBAL HEALTH. In the bustling Tygerberg University Hospital in Cape Town, a dedicated research team led by Lina Bergman, is on a mission to …  

Sara Bjursten and Anna Wenger are the recipients of the Assar Gabrielsson Prize 2024

17 May, 2024

AWARD. The Assar Gabrielsson Foundation has named Anna Wenger as the winner in the basic science research category and Sara Bjursten as the …  

A full day for PhD students focused on mental health

16 May, 2024

PHD STUDENTS. For the sixth time, PhD students at Sahlgrenska Academy were invited to PhD Day, organized by the Doctoral Student Council. The day …  

Kaj Blennow ranked highest in Sweden in neuroscience

16 May, 2024

AWARD. In this year's edition of the researcher ranking from Research.com in the field of neuroscience, Kaj Blennow is ranked 17th …  

Linda Wass is doing a postdoc at Stanford with ALF funding

14 May, 2024

ALF FUNDING. Biomedical Scientist Linda Wass has just settled in Stanford, California, where she will spend two years as a postdoc. She is the …  

Karin Nilsson wrote the Thesis of the Year at Sahlgrenska Academy in 2023

14 May, 2024

AWARD. Karin Nilsson, currently a postdoc at the Department of Internal Medicine and Clinical Nutrition, receives the faculty-wide Thesis of the …  

Some answers from the proposed members of the next Faculty Board

14 May, 2024

FACULTY ELECTIONS. The eight proposed members of the next Faculty Board hereby give some brief answers on how they want to contribute to the work …  

More news...

Sahlgrenska Academy

© University of Gothenburg
PO-Box 100, S-405 30 Gothenburg, Sweden
Phone: 00 46 31 786 0000

About the website

Elin Lindström is editor for Akademiliv.
Please feel free to send your ideas and comments to akademiliv@gu.se

Sign up for the Akademiliv newsletter:

Send you tips to Akademiliv

Do you have a suggestion for news, grants, seminars or an education?
Send an email to Elin Lindström Claessen